Vaccine signatures in humanized mice point to better understanding of infectious diseases

November 28, 2018, Princeton University
Researchers led by a team at Princeton University are exploring ways to make the mouse immune system more similar to that of humans, enabling mice to help in the search for new vaccines and treatments. Credit: Alexander Ploss and Florian Douam, Princeton University

Infectious diseases kill millions of people each year, but the search for treatments is hampered by the fact that laboratory mice are not susceptible to some human viruses, including killers like human immunodeficiency virus (HIV). For decades, researchers have turned to mice whose immune systems have been "humanized" to respond in a manner similar to humans.

Now a team at Princeton University has developed a comprehensive way to evaluate how immune responses of humanized mice measure up to actual humans. The looked at the mouse and immune responses to one of the strongest vaccines known, a yellow fever vaccine called YFV-17D. The comparison of these "vaccine signatures" showed that a newly developed humanized mouse developed at Princeton shares significant immune-system responses with humans. The study was published in the journal Nature Communications.

"Understanding immune responses to human pathogens and potential vaccines remains challenging due to differences in the way our human immune system responds to stimuli, as compared to for example that of conventional mice, rats or other animals," said Alexander Ploss, associate professor of molecular biology at Princeton University. "Until now a rigorous method for testing the functionality of the human immune system in such a model has been missing. Our study highlights an experimental paradigm to address this gap."

Humanized mice have been used in infectious disease research since the late 1980s. Yet without rigorous comparisons, researchers know little about how well the mice predict human responses such as the production of infection-fighting cells and antibodies.

To address this issue, researchers exposed the mice to the YFV-17D vaccine, which is made from a weakened, or attenuated, living yellow fever virus. Vaccines protect against future infection by provoking the production of antibodies and immune-system cells.

In , the researchers explored the effect of YFV-17D on conventional humanized mice. But the researchers found that the mice responded only weakly. This led them to develop a mouse with responses that are more similar to those of humans.

To do so, the researchers introduced additional human genes for immune system components—such as molecules that detect foreign invaders and chemical messengers called cytokines—so that the complexity of the engrafted human reflected that of humans. They found that the new mice have responses to YFV-17D that are very similar to the responses seen in humans. For example, the pattern of gene expression that occurs in to YFV-17D in the shared significant similarities to that of humans. This signature gene expression pattern, reflected in the "transcriptome," or total readout of all of the genes of the organism, translated into better control of the yellow fever virus infection and to immune responses that were more specific to yellow fever.

"Many vaccines have been generated empirically without profound knowledge of how they induce immunity," Douam said. "The next generation of mouse models, such as the one we introduced in our study, offer unprecedented opportunities for investigating the fundamental mechanisms that define the protective immunity induced by live-attenuated vaccines."

Mice bearing human cells or human tissues have the potential to aid research on treatments for many diseases that infect humans but not other animals, such as—in addition to HIV—Epstein Barr Virus, human T-cell leukemia virus, and Karposi sarcoma-associated herpes virus.

"Our study highlights the importance of human biological signatures for guiding the development of mouse models of disease," said Ploss. "It also highlights a path toward developing better models for human immune responses."

Explore further: Mouse model could shed new light on immune system response to Zika virus

More information: Florian Douam et al, Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses, Nature Communications (2018). DOI: 10.1038/s41467-018-07478-2

Related Stories

Mouse model could shed new light on immune system response to Zika virus

February 23, 2017
A new mouse model with a working immune system could be used in laboratory research to improve understanding of Zika virus infection and aid development of new treatments, according to a study published in PLOS Pathogens.

Mosquito spit may affect your immune system for days

May 17, 2018
Mosquito saliva alone—even in the absence of any pathogens—contains hundreds of proteins. Now, researchers reporting in PLOS Neglected Tropical Diseases have discovered that the interaction of these proteins with the ...

How the immune system protects against Zika-induced neurological symptoms

September 13, 2018
A type of immune cell that produces a protein called CD4 plays an important role in protecting mice infected with the Zika virus against severe neurological disease, according to a study published September 6 in the open-access ...

Animal model replicates human immune response against HIV, could revolutionize HIV vaccine research

July 18, 2012
One of the challenges to HIV vaccine development has been the lack of an animal model that accurately reflects the human immune response to the virus and how the virus evolves to evade that response. In the July 18 issue ...

Differences in immune responses due to age, sex and genetics

August 6, 2018
Age, sex, and specific human genetic variants are the key factors behind differences between immune responses among healthy humans, finds a study of 1,000 individuals carried out by EPFL and the Pasteur Institute.

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.